Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Lymphoma 74Lymphoma, Large B-Cell, Diffuse 55Lymphoma, Non-Hodgkin 54Glioblastoma 41Lymphoma, Mantle-Cell 40Lymphoma, Follicular 37Hodgkin Disease 36Central Nervous System Neoplasms 32Gliosarcoma 29Brain Neoplasms 28Astrocytoma 28Lymphoma, Large-Cell, Immunoblastic 26Burkitt Lymphoma 25Multiple Myeloma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Glioma 20Oligodendroglioma 16Lymphoma, B-Cell, Marginal Zone 15Neoplasms, Plasma Cell 14Leukemia 13Recurrence 10Lymphoma, B-Cell 9Lymphoma, T-Cell 8Waldenstrom Macroglobulinemia 6Lymphoma, T-Cell, Cutaneous 6Leukemia, Myeloid, Acute 6Ependymoma 6Lymphoma, T-Cell, Peripheral 5Lymphoma, Large-Cell, Anaplastic 5

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Melanoma × Carmustine × Clear all
NCT06626516 2025-11-28

Tebentafusp-tebn With LDT in Metastatic UM

Thomas Jefferson University

Phase 1/2 Recruiting
109 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00003346 2013-06-25

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
80 enrolled
Dermatologic

Melanoma

NCT00005961 2013-02-11

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡